Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma
-
Published:2023-12-22
Issue:1
Volume:25
Page:190
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Zupanc Cita12, Franko Alenka23, Štrbac Danijela24ORCID, Kovač Viljem24, Dolžan Vita5ORCID, Goričar Katja5ORCID
Affiliation:
1. Military Medical Unit-Slovenian Army, 1000 Ljubljana, Slovenia 2. Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia 3. Clinical Institute of Occupational Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia 4. Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia 5. Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
Abstract
Calretinin is a promising diagnostic biomarker for malignant mesothelioma (MM), but less is known about its prognostic role. Our aim was to evaluate the association between serum calretinin concentration or genetic factors and the survival or outcome of cisplatin-based chemotherapy in MM. Our study included 265 MM patients. Serum calretinin concentration was determined using ELISA. Patients were genotyped for seven polymorphisms in CALB2, E2F2, MIR335, NRF1, and SEPTIN7 using competitive allele-specific PCR. Nonparametric tests, logistic regression, and survival analysis were used for statistical analysis. Higher serum calretinin concentration was associated with shorter progression-free (PFS) (HR = 1.18 (1.02–1.37), p = 0.023) and overall survival (OS) (HR = 1.20 (1.03–1.41), p = 0.023), but the association was not significant after adjusting for clinical factors (HR = 1.05 (0.85–1.31), p = 0.653 and HR = 1.06 (0.84–1.34), p = 0.613, respectively). SEPTIN7 rs3801339 and MIR335 rs3807348 were associated with survival even after adjustment (HR = 1.76 (1.17–2.64), p = 0.007 and HR = 0.65 (0.45–0.95), p = 0.028, respectively). Calretinin concentration was higher in patients who progressed after treatment with cisplatin-based chemotherapy (1.68 vs. 0.45 ng/mL, p = 0.001). Calretinin concentration above 0.89 ng/mL was associated with shorter PFS and OS from the start of chemotherapy (HR = 1.88 (1.28–2.77), p = 0.001 and HR = 1.91 (1.22–2.97), p = 0.004, respectively), even after adjusting for clinical factors (p < 0.05). MIR335 rs3807348 was associated with a better response to chemotherapy (OR = 2.69 (1.17–6.18), p = 0.020). We showed that serum calretinin is associated with survival and chemotherapy treatment outcomes in MM and could serve as a predictive biomarker.
Funder
Javna Agencija za Raziskovalno Dejavnost RS
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference43 articles.
1. Štrbac, D., and Dolžan, V. (2022). Novel and Future Treatment Options in Mesothelioma: A Systematic Review. Int. J. Mol. Sci., 23. 2. Does size matter?—A population-based analysis of malignant pleural mesothelioma;He;Transl. Lung Cancer Res.,2020 3. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients;Kovac;Radiol. Oncol.,2012 4. Rondon, L., Fu, R., and Patel, M.R. (2023). Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma. Cancers, 15. 5. Deiana, C., Fabbri, F., Tavolari, S., Palloni, A., and Brandi, G. (2023). Improvements in Systemic Therapies for Advanced Malignant Mesothelioma. Int. J. Mol. Sci., 24.
|
|